EXPLORANCE
1.10.2018 07:02:05 CEST | Business Wire | Press release
Explorance, the leading provider of Learning Journey Analytics (LJA) solutions doubled its European client base in the past year. With the opening of new European offices, Explorance will be able to better partner with its growing European clients.
Improving the quality and relevance of teaching and learning in the European higher education market is the centre of the Bologna Process. The Yerevan Communiqué strengthened the call for better visibility of this policy area. According to the EUA Trends 2018 survey, 90% of the institutions use student feedback surveys to assess and enhance the quality of teaching. As the Bologna Process entices institutions to embrace a digitally-enabled approach, more institutions move toward the strategic use of digital tools to measure learning and teaching improvements.
“Before implementing Blue, we were using a dozen or so traditional questionnaires, combined with a few digital surveys. The wide range of individual solutions made it impossible to take full benefit of course evaluations,” says Mustapha Ali El-Ahmad, Senior Evaluation Consultant and Analyst at the Aarhus University. He adds, “Blue combines all these different questionnaires into one single solution, cleaning the data from the LMS & SIS, and automating the data analysis, while accommodating to different schools’ requirements.” Explorance’s Blue is built to support various feedback processes including course evaluations, competency development assessment, midterm reviews, applicant feedback, alumni perception analysis, student satisfaction, organisational surveys, and 360 degree reviews.
“The surge in demand for Explorance software and services in Europe indicates a growing need for proven online teaching and learning evaluation tools and increased trust in the Blue solution,” commented Ian Haugh, General Manager of the European offices. The new European office is located in Amsterdam and coordinates local activities across Europe and the UK. Local professional services are offered across Europe and customer service is provided 24/7 in multiple languages.
Blue surveys and evaluation solutions are fully localised with English, French, Spanish, German, Dutch, Swedish, Norwegian, Danish, Icelandic, Italian, Russian and Portuguese support. To support student mobility, Blue allows multiple languages to be used in one implementation at the same time. For an evaluation of your organisation’s needs, contact Explorance for a demonstration .
About Explorance
Explorance is a Learning Journey Analytics (LJA) provider that supports organisations in making the right decisions using fact-based feedback data. Through its Blue suite of products, organisations can assess needs, expectations, competencies, and monitor improvement over time.
Founded in 2003, Explorance is a privately held corporation headquartered in Montreal, Canada with business units in America, APAC, Europe, and the MENA region. As of 2014, Explorance has been ranked top employer by the Great Places to Work Institute®. Explorance's clients span a wide variety of learning organisations including academia, consulting firms, government institutions, and corporations. Learn more about Explorance .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180930005020/en/
Contact:
Gil Gruber gil@directobjective.com +1.514.238.7766
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom